Tina-quant® Cystatin C Gen. 2

Supporting the early detection of chronic kidney disease

  • Cystatin C is an aid for physicians to detect early chronic kidney diseases (stages 1 & and 2) and provides patients with an improved prognosis
  • The aim of therapy is to slow disease progression to stage 5 (ESRD) and the sooner treatment is initiated, the greater the benefit
  • Cystatin C is a better and earlier indicator of mild changes in eGFR, when creatinine values are still within the normal range
  • Cystatin C-based GFR assessments can make a real difference with respect to patient outcome - diagnosing chronic kidney disease at an early stage can add two or more years of ESRD-free survival and, in some patients, ESRD may actually be prevented


Tina-quant Cystatin C Chart1 Details view

Figure: Cystatin C is the marker of choice for early detection of CKD (stages 1 and 2) contributing to improved patient outcome

Tina-quant Cystatin C Chart2 Details view

Figure: The limitations of serum creatinine mean that patients with early stage kidney disease may go undetected

The test is performed via Roche's Turbidimetry technology for homogeneous immunoassay detection.

Earlier and more reliable assessment of renal function

Clinical benefit

  • Cystatin C is a more reliable, early marker of renal dysfunction compared with creatinine
  • Early detection and treatment can prevent or delay adverse outcomes of renal failure
  • Cystatin C is a better indicator of mild changes in GFR - at which stage creatinine values are still within the normal range

Benefits for the lab

  • Cystatin C concentration is not influenced by inflammation, muscle mass, gender or age
  • Standardized to the international reference material ERM-DA 471/IFCC
  • Long onboard stability and calibration frequency mean economical reagent usage and cost efficiencies

Studies demonstrate that the progression of end stage renal disease may be delayed or prevented:
National Kidney Disease Education Program, “Chronic Kidney Disease in the United States”, Presentation page 23.

More than 11 million patients in US may go undetected with creatinine-based GFR assessments due to creatinine-blind area:
Coresh, J., Byrd-Holt, D., Astor, B.C., Briggs, J.P., Eggers, P.W., Lacher, D.A., Hostetter, T.H. (2005). Chronic kidney disease awareness, prevalence, and trends among US adults, 1999 to 2000. J Am Soc Nephrol. 16, 180–188.

Conclusion: 
Number of US Patients suffering chronic kidney disease (CKD); about 26 million American adults of the general population. More than 11 million patients in US may go undetected with creatinine-based GFR assessments due to creatinine-blind area.


Tina-quant Cystatin C Proof Sources Details view

Figure: Not detecting chronic kidney disease in the early stages (stages 1 and 2) means that half of patients miss the advantages of early treatment